Skip to content
PaperFren

Organic synthesis

DOS fragments grow hits in several directions at once

Kidd SL, Fowler E, Reinhardt T, et al. · Chemical science · 2020

Open access · cc by · source: Europe PMC

A modular diversity-oriented fragment library gave crystallographic hits on several proteins and then short, cheap sequences to many analogues, including a first covalent PBP3 fragment.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.

Inspect source passages

DOS fragments grow hits in several directions at once

These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.

Compound 1 was the first binder among about 1300 previous fragment soaks.

This initial screen resulted in the serendipitous discovery of 1 as a covalent binder of PBP3 (PDB: 6Y6Z, ), which strikingly was the first binder identified amongst approximately 1300 previous fragment soaks (see Table S1 for further details).

The DOS library was used at 500 mM in d6-DMSO.

The DOS library was screened in a racemic fashion to provide both enantiomers and was used in a 500 mM format in d 6 -DMSO.
Read passages in the original paper

Key findings

Compound 1 was the first binder after ~1300 prior fragment soaks on PBP3, covalently linking Ser294. Up to 14 analogues per hit were accessible; only p-fluoro analogue 28 of nine aromatics soaked into CFI crystals; 1,4-isoxazole 29 bound but 1,5-isomer 30 did not.

Methodology

Authors screened a racemic DOS fragment set (500 mM in d6-DMSO) by X-ray crystallography, then used designed exit vectors—amide couplings, click chemistry, Cu(I) lactonizations—to elaborate hits such as the PBP3 covalent binder 1.

Limitations

The paper does not report optimized cellular potency or a clinical candidate—only early crystallographic hits and synthetic tractability.

Related papers in this topic

Same topic cluster — not a recommendation engine.